Skip to main content

Advertisement

SpringerLink
Log in

Alfacalcidol improves muscle power, muscle function and balance in elderly patients with reduced bone mass

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

We investigated the effect of daily therapy with 1 mcg alfacalcidol (Doss®-TEVA/AWD-pharma) on muscle power, muscle function, balance performance and fear of falls in an open, multi-centered, uncontrolled, prospective study on a cohort of patients with reduced bone mass. Among the 2,097 participants, 87.1% were post-menopausal women and 12.9% were men. Mean age was 74.8 years and mean body mass index (BMI) 26.3 kg/m². A total of 75.3% of the study population had osteoporosis, 81% a diagnosis of “increased risk of falls” and 70.1% had a creatinine clearance (CrCl) of <65 ml/min. Participants underwent muscle function and muscle power tests at onset and after 3 and 6 months: the timed up and go test (TUG) and the chair rising test (CRT). At baseline and after 6 months, participants performed the tandem gait test (TGT) and filled out a questionnaire evaluating fear of falling. Successful performance in the muscle tests is associated with a significantly lower risk of falls and non-vertebral fractures in elderly patients (successful test performance: TUG ≤ 10 s (sec), CRT ≤ 10 s, TGT ≥ 8 steps). A significant improvement in the performance of the two muscle tests was proved already after 3 months of treatment with alfacalcidol and further increased by the end of the therapeutic intervention. There were significant increases in the number of participants able to successfully perform the tests: 24.6% at baseline and 46.3% at the end of trial for the TUG (P < 0.0001) and 21.7% at baseline and 44.2% at the end for the CRT test (P = 0.0001). The mean time used for the TUG was decreased by 3.0 s from the average onset value of 17.0 s and by 3.1 s from the initial average 16.5 s for the CRT. The percentage of participants able to perform the balance test (TGT) increased from 36.0% at onset to 58.6% at the end of the trial (P < 0.0001). An increased fear of falling was reduced by the end of the study in 74.4% of the patients. Throughout the study, there were 26 adverse drug reactions in 11 out of 2,097 patients (incidence 0.52%). No serious adverse drug reactions and no cases of hypercalcemia were documented. We conclude that treatment with alfacalcidol is safe, increases muscle power, muscle function and balance and reduces fear of falls. The significant improvement in the three muscle and balance tests and fear of falls may have a preventative effect on falls and fractures. We suggest that the quantitative risk tests used in this study could be reliable surrogate parameters for the risk of falls and fractures in elderly patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Järvinen TLN, Sievanen H, Khan KM, Heinonem A, Kannis P (2008) Shifting the focus in fracture prevention from osteoporosis to falls. Brit Med J 336:124–126

    PubMed  Google Scholar 

  2. American Geriatrics Society (2001) British Geriatrics Society and American Academy of Orthopaedic Surgeons panel on falls prevention. J Am Geriatr Soc 49:664–672

    Google Scholar 

  3. Birge SJ (2008) Osteoporotic fractures: a brain or bone disease? Curr Osteoporotic Rep 6:57–61

    Google Scholar 

  4. Runge M, Schacht E (2005) Multifactorial pathogenesis of falls as a basis for multifactorial interventions. J Musculoskelet Neuronal Interact 5(2):127–134

    PubMed  CAS  Google Scholar 

  5. Pfeifer M, Begerow B, Minne HW, Abrams C, Nachtigall D, Hansen C (2000) Effects of a short term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res 15(6):1113–1118

    PubMed  CAS  Google Scholar 

  6. Bischoff-Ferrari HA, Dawson-Hughes B, Willet WC, Stahelin HB, Bazemore MG, Zee RY, Wong JB (2004) Effect of vitamin d on falls: a meta analysis. JAMA 291:1999–2006

    PubMed  CAS  Google Scholar 

  7. Dukas L, Bischoff HA, Lindpaintner LS, Schacht E, Birkner-Binder D, Damm T, Thalmann B, Stahelin HB (2004) Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of 500 mg daily. J Am Geriatr Soc 52:1–7

    Google Scholar 

  8. Gallagher JC (2004) The effects of calcitriol on falls and fractures and physical performance tests. J Steroid Biochem Mol Biol. 89–90:497–501

    PubMed  Google Scholar 

  9. Richy F, Dukas L, Schacht E (2008) Differential effects of d-hormone analogs and native vitamin d on the risk of falls: a comparative meta-analysis. Calcif Tissue Int 82:102–107

    PubMed  CAS  Google Scholar 

  10. Schacht E (2008) Reduction of falls and osteoporotic fractures: plain vitamin d or d-hormone analogs? Geriatr Gerontol Int 8(Suppl 1):S16–S25

    Google Scholar 

  11. Schacht E, Richy F, Reginster J-Y (2005) The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures. J Musculoskelet Neuronal Interact 5:273–284

    PubMed  CAS  Google Scholar 

  12. Boland R (1986) Role of vitamin d in skeletal muscle function. Endocr Rev 7:434–447

    PubMed  CAS  Google Scholar 

  13. Endo I, Inoue D, Mitsui T, Umaki Y, Akaike M, Yoshizawa T, Kato S, Matsumoto T (2003) Deletion of vitamin d receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology 144(12):5138–5144

    PubMed  CAS  Google Scholar 

  14. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL (2007) Prevalence of abnormal serum vitamin D, PTH, calcium and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71:31–38

    PubMed  CAS  Google Scholar 

  15. Dukas LC, Schacht E, Mazor Z, Stahelin HB (2005) A new significant and independent risk factor for falls in elderly men and women: a low creatinine clearance of less than 65 ml/min. Osteoporos Int 16(3):332–338

    PubMed  CAS  Google Scholar 

  16. Dukas L, Schacht E, Stahelin HB (2005) In elderly men and women treated for osteoporosis a low creatinine clearance of <65 ml/min is a risk factor for falls and fractures. Osteoporos Int 16(12):1683–1690

    PubMed  CAS  Google Scholar 

  17. Gallagher JC, Rapuri PB, Smith LM (2007) An age related decrease in creatinine clearance is associated with an increase in number of falls in untreated women but not in women receiving calcitriol. J Clin Endocrinol Metab 92:51–58

    PubMed  CAS  Google Scholar 

  18. Ensrud KE, Lui L-Y, Taylor BC, Ishani A, Shlipak MG, Stone KL, Cauley JA, Jamal SA, Antoniucci DM (2007) Cummings SR; for the study of osteoporotic fractures research group. Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med 167:133–139

    PubMed  Google Scholar 

  19. Dukas L, Schacht E, Runge M (2009) Independent from muscle power and balance performance a creatinine clearance below 65 ml/min is a significant and independent risk factor for falls and fall-related fractures in elderly men and women diagnosed with Osteoporosis. Published online in Osteoporos Int doi:10.1007/s00198-009-1064-1

  20. Dukas L, Schacht E, Runge M, Ringe JD 2010 A 6 month therapy with alfacalcidol leads to a significant increase in muscle power and balance and significantly reduces the number of fallers and falls. Drug Research (accepted for publication in March 2010)

  21. Dukas LC, Schacht E, Runge M (2008) A 6 month therapy with alfacalcidol leads to a significant increase in muscle power and balance and significantly reduces the number of fallers and falls. Osteoporos Int 19(2):368

    Google Scholar 

  22. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31–41

    PubMed  CAS  Google Scholar 

  23. DVO Leitlinie. Osteoporose bei postmenopausalen Frauen DVO-Leitlinie 2003 (serial online); (46 screens). Available from URL: http://www.lutherhaus.de/osteo.leitlinien-dvo/

  24. DVO Leitlinie zur Prophylaxe, Diagnostik und Therapie der Osteoporose. DVO Leitlinie 2009. http://www.dv-osteologie.org.uploads/leitlinien/DVO-Leitninie-2009LangfassungVersion06-03-09.pdf

  25. Podsialdo D, Richardson S (1991) The timed up and go test: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 39(2):142–148

    Google Scholar 

  26. Shumway-Cook A, Brauer S, Woollacott M (2000) Predicting the probability for falls in community-dwelling older adults using the timed up and go test. Phys Ther 80:896–903

    PubMed  CAS  Google Scholar 

  27. Bischoff HA, Stahelin HB, Monsch AU, Iverson M, Weyh A, von Dechend M, Akos R, Conzelmann M, Dick W, Theiler R (2003) Identifying a cut-off point for normal mobility: a comparison of the timed “up and go” test in community dwelling and institutionalized elderly women. Age Ageing 32:315–320

    PubMed  Google Scholar 

  28. Zhu K, Devine A, Prince RL (2008) Timed up and go test and bmd as predictors of fractures: a 10 year longitudinal study. J Bone Min Res 23:S119

    Google Scholar 

  29. Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB (1995) Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Eng J Med 332:556–561

    CAS  Google Scholar 

  30. Gill TM, Williams CS, Tinetti ME (1995) Assessing risk for the onset of functional dependence among older adults: the role of physical performance. J Am Geriatr Soc 43:603–609

    PubMed  CAS  Google Scholar 

  31. Chu LW, Pei CK, Chiu A et al (1999) Risk factors for falls in hospitalized older medical patients. J Gerontol Med Sci 54A:M38–M43

    Google Scholar 

  32. Danneskiold-Samsoe B, Kofod V, Munter J (1984) Muscle strength and functional capacity in 78–81 year old men and women. Eur J Appl Physiol 52:310–314

    CAS  Google Scholar 

  33. Tinetti ME, Williams CS (1998) The effect of falls and fall injuries on functioning in community-dwelling older persons. J Gerontol A Biol Sci Med Sci 53(2):M112–M119

    PubMed  CAS  Google Scholar 

  34. Lau KHW, Baylink DJ (1999) Vitamin D therapy of osteoporosis: plain vitamin D therapy vs. active vitamin d analog (d-hormone) therapy. Calcif Tissue Int 65:295–306

    PubMed  CAS  Google Scholar 

  35. Vellas BJ, Wayne SJ, Romero LJ, Baumgartner RN, Garry PJ (1997) Fear of falling and restriction of mobility in elderly fallers. Age Aging 26:189–193

    CAS  Google Scholar 

  36. Arfken CL, Lach HW, Birge SJ, Miller JP (1994) The prevalence and correlates of fear of falling in elderly persons living in the community. Am J Public Health 84:565–570

    PubMed  CAS  Google Scholar 

  37. Jassal SK, von Muhlen D, Barrett-Connor E (2007) Measure of renal function, bmd, bone loss and osteoporotic fracture in older adults: the rancho bernardo study. J Bone Miner Res 22:203–210

    PubMed  CAS  Google Scholar 

  38. Gryfe CI, Amies A, Ashley MJ (1997) A longitudinal study of falls in an elderly population: incidence and morbidity. Age Ageing 6(4):201–210

    Google Scholar 

  39. Klawansky S, Komaroff E, Cavanaugh PF, Mitchell DY, Gordon MJ, Connelly JE, Ross SD (2003) The relationship between age, renal function and bone mineral density in the us population. Osteoporos Int 14:570–576

    PubMed  CAS  Google Scholar 

  40. Dukas L, Schacht E, Mazor Z, Staehelin HB (2005) Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of <65 ml/min. Osteoporos Int 16(2):198–203

    PubMed  CAS  Google Scholar 

  41. Richy F, Deroisy R, Lecart M-P, Hanssens L, Mawet A, Reginster J-Y (2005) D-hormone analog alfacalcidol: an update on its role in post-menopausal osteoporosis and rheumatoid arthritis management. Aging Clin Exp Res 17:133–142

    PubMed  CAS  Google Scholar 

  42. Ringe JD, Cöster A, Meny T, Schacht E, Umbach R (1999) Treatment of glucocorticoid induced osteoporosis with alfacalcidol/calcium vs. vitamin d/calcium. Calcif Tissue Int 65:337–340

    PubMed  CAS  Google Scholar 

  43. Scharla SH, Schacht E, Lempert UG (2005) Alfacalcidol vs Plain Vitamin D in Inflammation Induced Bone Loss. J Rheumatol. 32,76 (Suppl): 26–32

    Google Scholar 

  44. Bischoff HA, Staehelin HB, Urscheler N, Ehrsam R, Vonthein R, Perrig-Chiello P, Tyndall A, Theiler R et al (1999) Muscle strength in the elderly : its relation to vitamin d metabolites. Arch Phys Med Rehabil 80(1):54–58

    PubMed  CAS  Google Scholar 

  45. Dukas L, Staehelin HB, Schacht E, Bischoff HA (2005) Better functional mobility in community-dwelling elderly is related to d-hormone serum levels and to a daily calcium intake. Nutr Health Aging 9(5):347–351

    CAS  Google Scholar 

  46. Sorensen OH, Lund BI, Saltin B, Lund BJ, Andersen RB, Hjorth L, Melsen F, Mosekilde L (1979) Myopathy in bone loss of aging: improvement by treatment with 1-alpha-hydroxycholecalciferol and calcium. Clin Sci 56(2):157–161

    PubMed  CAS  Google Scholar 

  47. Verhaar HJJ, Samson MM, Jansen PAF, de Vreede PL, Manten JW, Duursma SA (2000) Muscle strength, functional mobility and vitamin d in older women. Aging Clin Exp Res 12:455–460

    CAS  Google Scholar 

  48. Sasaki H, Miyakoshi N, Kasukawa Y, Maekawa Y, Kamo K, Shimada Y (2008) Effects of alfacalcidol on bone and skeletal muscle in glucocorticoid treated rats. J Bone Miner Res 23:427

    Google Scholar 

  49. Koike T, Okawa T, Wada M, Kita T, Takaoka K (2003) Effects of a long-term alfacalcidol or calcitonin administration on body sway in Japanese elderly women. J Bone Miner Res 18(S2):S168

    Google Scholar 

  50. Schacht E, Richy F (2009) Reduction of falls in elderly. The central role of alfacalcidol in a multi-dimensional paradigm. Internet J Epidemiol 7(1)

  51. Ringe JD, Schacht E (2009) Potential of alfacalcidol for reducing increased risk of falls and fractures. Rheumatol Internat 29:1177–1185

    CAS  Google Scholar 

  52. Faulkner KA, Cauley JA, Zmuda JM, Landsittel DP, Newman AB, Studenski SA, Redfern MS, Ensrud KE, Fink HA, Lane NE, Nevitt MC (2006) Higher 1.25-dihydroxyvitamin D3 concentrations associated with lower fall rates in older community-dwelling women. Osteoporos Int 17(9):1318–1328

    PubMed  CAS  Google Scholar 

  53. Tilyard MW, Spears GF, Thomson J, Dovey S (1992) Treatment of post-menopausal osteoporosis with calcitriol or calcium. N England J Med 326(6):357–362

    CAS  Google Scholar 

  54. Tanizawa T, Imura K, Ishii Y, Nishida S, Takano Y, Mashiba T, Endo N, Takahashi HE (1999) Treatment with active vitamin d metabolites and concurrent treatments in the prevention of hip fractures: a retrospective study. Osteoporosis Int 9:163–170

    CAS  Google Scholar 

  55. Sato Y, Maruoka H, Oizumi K (1997) Amelioration of hemiplegia-associated osteopenia more than 4 years after stroke by 1alpha-hydroxyvitamin d3 and calcium supplementation. Stroke 28:736–739

    PubMed  CAS  Google Scholar 

  56. Sato Y, Manabe S, Kuno H, Oizumi K (1999) Amelioration of osteopenia and hypovitaminosis d by 1alpha-hydroxyvitamin d3 in elderly patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 66:64–68

    PubMed  CAS  Google Scholar 

  57. Richy F, Ethgen O, Bruyere O, Reginster JY (2004) Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 15:301–310

    PubMed  CAS  Google Scholar 

  58. O’Donnell S, Moher D, Thomas K, Hanley DA, Cranney A (2008) Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls. J Bone Mineral Metab 26:531–542

    Google Scholar 

Download references

Acknowledgments

We are indebted to Egon Pfarr, Director Statistics and Data Management, AMS Advanced Medical Services GmbH, Mannheim, Germany, for his precise and meticulous statistical analysis.

Author information

Authors and Affiliations

  1. ZORG (Zurich Osteoporosis Research Group), Zollikerberg, Switzerland

    E. Schacht

  2. Med. Clinic 4, Klinikum Leverkusen, West German Osteoporosis Center, University of Cologne, 51375, Leverkusen, Germany

    Johann D. Ringe

Authors
  1. E. Schacht
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johann D. Ringe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Johann D. Ringe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schacht, E., Ringe, J.D. Alfacalcidol improves muscle power, muscle function and balance in elderly patients with reduced bone mass. Rheumatol Int 32, 207–215 (2012). https://doi.org/10.1007/s00296-010-1607-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-010-1607-y

Keywords

Search

Navigation